Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Orexin Receptor Antagonist [EPC]

Known as: Orexin Receptor Antagonist 
National Institutes of Health

Related topics

Related topics

2 relations
Orexin Receptor AntagonistsOrexin Receptor Antagonists [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Antistress effects of Kampo medicine “Yokukansan” via regulation of orexin secretion
Objective Various stressors induce stress responses through the hypothalamic–pituitary–adrenal and the sympathetic–adrenal… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
Abstract Background We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with… Expand
2016
2016
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
Background: Filorexant (MK-6096) is an orexin receptor antagonist; here, we evaluate the efficacy of filorexant in the treatment… Expand
  • figure 2
2016
2016
Suvorexant: A boon for Sleepless Nights
Insomnia is characterized by difficulty in falling asleep, difficulty maintaining sleep, or experiencing nonrestorative sleep… Expand
  • figure 1
2015
2015
Suvorexant: The first orexin receptor antagonist to treat insomnia
Primary insomnia is mainly treated with drugs acting on benzodiazepine receptors and a few other classes of drugs used for… Expand
Review
2014
Review
2014
Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Insomnia persistently affects the quality and quantity of sleep. Currently approved treatments for insomnia primarily target… Expand
2014
2014
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
Almorexant, a tetrahydroisoquinoline orexin receptor antagonist and first representative of a new class of compounds for the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2014
2014
Quantitative Proteomics in Laser Capture Microdissected Sleep Nuclei From Rat Brain
Abstract The combination of stable isotope labeling of amino acids in mammals (SILAM) and laser capture microdissection (LCM) for… Expand
2014
2014
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
Almorexant, a dual orexin receptor antagonist, was investigated for the treatment of insomnia. The following observations… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE